Role of Ca 15-3 in patients with biochemically suspected prostate cancer and multiple negative ultrasound-guided prostate biopsies

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 1, 2003, Pages 45-49

  Falsaperla, M ^a   Morgia, G ^b   Giammusso, B ^a   Condorelli, S V ^a   Saita, A ^a   Marchese, F ^a   Spampinato, A ^a   Motta, M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Ca 15 3; Prostate cancer; PSA; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CHRONIC PROSTATITIS; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PALPATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; CA-15-3 ANTIGEN; ENDOSONOGRAPHY; FALSE NEGATIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037252095     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500615     Document Type: Article

References (14)

1. Luthgens M. Definition. In Luthgens M, Schlegel G (eds). Clinical Use of Tumor Marker System. Leonberg: Tumor Diagnostic, 1989, pp. 3-4.
2. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC. Prostate specific antigen in the preoperative and post-operative evolution of localized prostate cancer treated with radical prostatectomy. J Urol 1998; 139: 766-772.
3. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142(4): 1011-1017.
4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. New Engl J Med 1991; 324(17): 1156-1161.
5. Crawford ED, DeAntoni EP. PSA as a screening test for prostate cancer. Urol Clin N Am 1993; 20(4): 637-646.
6. Glenski WJ, Malek RS, Myrtle JF, Oesterling JE. Sustained substantially increased concentration of prostate specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clin Proc 1992; 67(3): 349-352.
7. Chu TM. Prostate specific antigen and early detection of prostate cancer. Tumour Biol 1997; 18(2): 123-134.
8. Cohen R, Zucchelli GC, Fraysse M, Pilo A, Rigault MY, Grillet S, Bizollon CA. 'Oncocheck': an international external quality assessment scheme for immunoassays of tumor markers. Nucl Med Biol 1994; 21(3): 483-493.
9. Kruse R, Geilenkeuser WJ, Rohle G. Interlaboratory surveys of the determination of tumour markers scatter and repeatability of the results. Eur J Clin Chem Clin Biochem 1993; 31(3): 139-146.
10. Alivizatos G, Dimopoulos A, Mitropoulos D, Alevizou K, Bougas D, Pantazopoulos D. Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma. Arch Esp Urol 1992; 45(3): 269-272.
11. Lopez LA, Del Villar V, Ulla M, Fernandez F, Fernandez LA, Santos I, Rabadan L, Gutierrez M. Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing 1996; 25(1): 45-50.
12. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer 1991; 15(6): 299-360.
13. Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, Grundler S, Gregorits M, Strasser M. Ca 15-3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumour Biol 1991; 12(3): 138-148.
14. Lotzniker M, Pavesi F, Scarabelli M, Vadacca G, Franchi M, Moratti R. Tumour associated antigens CA 15.3 and CA 125 in ovarian cancer. Int J Biol Markers 1991; 6(2): 115-121.